Johnson Health Tech Co Ltd (1736) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Johnson Health Tech Co Ltd TWD 143, price TWD 128, upside +11.9%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Johnson Health Tech Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Johnson Health Tech .Co., Ltd., together with its subsidiaries, manufacturers and sells fitness equipment in the Americas, Europe, Asia, and internationally.
Show more
Johnson Health Tech .Co., Ltd., together with its subsidiaries, manufacturers and sells fitness equipment in the Americas, Europe, Asia, and internationally. The company offers cardiopulmonary resuscitation fitness machines, weight training machines, electric massage chairs and related motors, and instruments and electronic control panels, as well as instruments and electrical chairs, and related motors. It is also involved in buying and selling bodybuilding and weight training machines, and hearing aid; research and development, manufacturing, and sales of massage chair and sports equipment; provision of video streaming and transmission, and catering services; food wholesale; leasing business; and cultural communication activities. The company sells its products under the MATRIX, Vision Fitness, BowFlex, Schwinn, and Horizon brands. Johnson Health Tech .Co., Ltd. was incorporated in 1975 and is headquartered in Taichung, Taiwan.
Stock analysis
Johnson Health Tech Co Ltd (1736) currently trades at 127.50 TWD, while our model-based Fair Value estimate is 142.67 TWD, implying the stock looks roughly 10.6% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 172.84 TWD per share, and 15 of the 26 models we run sit above the 127.50 TWD price.
Bear case: the Asset-Based group reads lowest at 30.32 TWD, and 11 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: 67.36 TWD (bear) to 205.65 TWD (bull), the price of 127.50 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Consumer Cyclical sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Johnson Health Tech Co Ltd reported revenue of 54.3B TWD in FY2025 versus 30.8B TWD in FY2021, a compound +15.3%/yr. Reported net income was 2.8B TWD in FY2025, compounding +129.4%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 38.7B TWD (≈ $1.2B) · P/E ratio 14.1 · P/S ratio 0.71 · EPS (TTM) 9.06 TWD · Dividend yield 3.0% · Net margin 5.1% · Return on equity 18.6% · Return on assets (EBIT) 4.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at 38% fair-value upside, at 12%, 1736 screens richer than that median.
Fair Value models
Bear 67.36 TWDFair Value 142.67 TWDBull 205.65 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (6.63 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+13.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Start year 2020 (pandemic). Over 10 years: +12.3% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +35.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.2%
Dividend (yield on the price)3.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.32% vs 14%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 7%
Start year 2020 (pandemic)
⚠ Approximate: the rate leans on 2025, which sits 287% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+33.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +31.9% a year for the price.
Compare Johnson Health Tech Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Leisure · 189 stocks
Beats the industry median on 10/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside+12% · Above median
Profitability
Return on equity (TTM)19% · Top 25%
Return on assets5% · Above median
Net margin (TTM)5% · Above median
Operating margin (TTM)−1% · Below median
Growth and dividend
Revenue growth11% · Above median
Dividend yield (TTM)3.0% · Above median
Balance sheet
Debt / equity0.51× · Highest 25%
Valuation Multiplesvs Leisure median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Johnson Health Tech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1736
Frequently asked questions
Is Johnson Health Tech Co Ltd (1736) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 142.67 TWD versus a price of 127.50 TWD, about +12% upside (undervalued).
What is the fair value of 1736?
Our model-based fair value for Johnson Health Tech Co Ltd is 142.67 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 127.50 TWD.
What is the quality score of 1736?
Johnson Health Tech Co Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Johnson Health Tech Co Ltd (1736)?
Our model-based price target is the fair value of 142.67 TWD (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 67.36 TWD, optimistic scenario 205.65 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Johnson Health Tech Co Ltd stock forecast for 2026?
Our models put fair value at 142.67 TWD, about +12% upside versus a price of 127.50 TWD (undervalued). Cautious scenario 67.36 TWD, optimistic scenario 205.65 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Johnson Health Tech Co Ltd (1736)?
Johnson Health Tech Co Ltd reported trailing-twelve-month revenue of about 55.5B TWD (latest available figure, as of Sep 24, 2026).
Does Johnson Health Tech Co Ltd pay a dividend?
Johnson Health Tech Co Ltd currently shows a dividend yield of about 2.96% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Johnson Health Tech Co Ltd (1736)?
For today's price to be fair in a discounted-cash-flow model, Johnson Health Tech Co Ltd would have to grow free cash flow by +33.9 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 1736 use?
Our models discount Johnson Health Tech Co Ltd at 10.3 %: a base by market capitalisation (small), damped by beta 0.19, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Johnson Health Tech Co Ltd that is +33.9 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Johnson Health Tech Co Ltd (1736) delivered so far?
Over the past 5 years revenue at Johnson Health Tech Co Ltd grew +13.9 % a year. The price currently implies +33.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Johnson Health Tech Co Ltd (1736) growing?
The median revenue growth in the sector is +2.6 % a year. That is the yardstick for the growth priced into Johnson Health Tech Co Ltd (+33.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Johnson Health Tech Co Ltd (1736)?
The free-cash-flow yield on the price is 2.06 %: that much free cash flow Johnson Health Tech Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Johnson Health Tech Co Ltd (1736)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Johnson Health Tech Co Ltd it is 142.67 TWD per share (as of Sep 24, 2026), against a price of 127.50 TWD. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Johnson Health Tech Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 1736 trades below its calculated fair value: price 127.50 TWD, fair value 142.67 TWD, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1736?
No. The price is what the market pays today (127.50 TWD); the fair value is what the company's own numbers justify (142.67 TWD). For Johnson Health Tech Co Ltd the two are 15.17 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Johnson Health Tech Co Ltd worth?
The market values Johnson Health Tech Co Ltd at about 38.7B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 127.50 TWD; our models calculate a fair value of 142.67 TWD per share.
What do the bullish and bearish scenarios say about 1736?
Our models span a range for Johnson Health Tech Co Ltd: cautious scenario 67.36 TWD, base 142.67 TWD, optimistic 205.65 TWD per share (as of Sep 24, 2026, price 127.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1736?
Johnson Health Tech Co Ltd trades at a price-to-earnings ratio of 14.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 142.67 TWD is built from several models across several years. Other multiples: PEG 0.6, P/B 2.8, P/S 0.7, EV/EBITDA 10.5.
What is the PEG ratio of 1736?
The PEG ratio of Johnson Health Tech Co Ltd is 0.57 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Johnson Health Tech Co Ltd (1736)?
Balance-sheet figures for Johnson Health Tech Co Ltd (as of Sep 24, 2026): return on equity 18.6%, debt of 0.51 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 1736 from its 52-week high?
Johnson Health Tech Co Ltd trades at 127.50 TWD, about 30% below its 52-week high of 183.00 TWD and 18% above the low of 108.00 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 142.67 TWD is for.
Which stocks are comparable to Johnson Health Tech Co Ltd?
From the same area (Consumer Cyclical) we also value ANTA Sports Products Limited, Pop Mart International Group, Amer Sports, Inc, Hasbro, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Johnson Health Tech Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 127.50 TWD, calculated fair value 142.67 TWD (+12%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1736 calculated?
We run Johnson Health Tech Co Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 142.67 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Johnson Health Tech Co Ltd currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Johnson Health Tech Co Ltd (1736)?
The closing price on Sep 24, 2026 was 127.50 TWD. Our model-based fair value is 142.67 TWD, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Johnson Health Tech Co Ltd right now?
The model range is unusually wide (67.36 TWD to 205.65 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Johnson Health Tech Co Ltd (1736) come from?
Earnings per share at Johnson Health Tech Co Ltd grew +4.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.3 %, EBIT margin +2.1 %, tax rate −1.4 %, residual (interest, one-offs) −6.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Johnson Health Tech Co Ltd
How large is the market capitalisation of Johnson Health Tech Co Ltd (1736)?
The market capitalisation of Johnson Health Tech Co Ltd is 38.7B TWD (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Johnson Health Tech Co Ltd (1736)?
The price-to-sales ratio of Johnson Health Tech Co Ltd is 0.71 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Johnson Health Tech Co Ltd (1736)?
Earnings per share at Johnson Health Tech Co Ltd are 9.06 TWD (price ÷ EPS = P/E 14.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Johnson Health Tech Co Ltd (1736)?
The dividend yield of Johnson Health Tech Co Ltd is 3.0% (payout 41.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Johnson Health Tech Co Ltd (1736)?
The net margin of Johnson Health Tech Co Ltd is 5.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Johnson Health Tech Co Ltd (1736)?
The return on equity (ROE) of Johnson Health Tech Co Ltd is 18.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Johnson Health Tech Co Ltd (1736)?
On an EBIT basis the return on assets of Johnson Health Tech Co Ltd is 4.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Johnson Health Tech Co Ltd (1736)?
The operating margin of Johnson Health Tech Co Ltd is −0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Johnson Health Tech Co Ltd (1736)?
Revenue at Johnson Health Tech Co Ltd is growing +11.1% versus a year earlier (3y avg +17.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Johnson Health Tech Co Ltd (1736)?
Earnings per share at Johnson Health Tech Co Ltd are growing −91.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Johnson Health Tech Co Ltd (1736) carry?
The net debt of Johnson Health Tech Co Ltd is 16.1B TWD (fiscal year 2025, ≈ 20.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Johnson Health Tech Co Ltd in the live analysis
One click puts Johnson Health Tech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
